BACH2 is a B-cell specific transcription factor that is required for germinal center formation and blocks plasma cell differentiation by repressing the PRDM1 [28], [29], [30]; BTG2 has anti-proliferative activity [31]; EBF1 is a key lineage determination transcription factor during the transition between pro-B to pre-B cells [32]; and TCL1A, an activator for AKT kinase, is known to be an immunohistochemical marker of adverse outcome of DLBCL [33]. The gene discussed is TCL1A; the disease is diffuse large B-cell lymphoma.